Augusto J. Mendes

Dr. Augusto J. Mendes

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
AMAugusto J. Mendes
Augusto J. Mendes
FRFederica Ribaldi
Federica Ribaldi
ALAurelien Lathuiliere
Aurelien Lathuiliere
NANicholas J. Ashton
Nicholas J. Ashton
SJShorena Janelidze
Shorena Janelidze
GFGiovanni B. Frisoni
Giovanni B. Frisoni
Background and objective: Phosphorylated tau (p-tau) 217 has recently received attention because it seems more reliable than other p-tau variants for identifying Alzheimer’s disease (AD) pathology. Thus, we aimed to compare the diagnostic accuracy of plasma and CSF p-tau217 with p-tau181 and p-tau231 in a memory clinic cohort. Methods: The study included 114 participants (CU = 33; MCI = 67; Dementia = 14). The p-tau variants were correlated versus continuous measures of amyloid (A) and tau (T)-PET. The p-tau phospho-epitopes were assessed through: (i) effect sizes (δ) between diagnostic and A ± and T ± groups; (ii) receiver operating characteristic (ROC) analyses in A-PET and T-PET. Results: The correlations between both plasma and CSF p-tau217 with A-PET and T-PET (r range 0.64–0.83) were stronger than those of p-tau181 (r range 0.44–0.79) and p-tau231 (r range 0.46–0.76). Plasma p-tau217 showed significantly higher diagnostic accuracy than p-tau181 and p-tau231 in (i) differences between diagnostic and biomarker groups (δrange: p-tau217 = 0.55–0.96; p-tau181 = 0.51–0.67; p-tau231 = 0.53–0.71); (ii) ROC curves to identify A-PET and T-PET positivity (AUCaverage: p-tau217 = 0.96; p-tau181 = 0.76; p-tau231 = 0.79). On the other hand, CSF p-tau217 (AUCaverage = 0.95) did not reveal significant differences in A-PET and T-PET AUC than p-tau181 (AUCaverage = 0.88) and p-tau231 (AUCaverage = 0.89). Discussion: Plasma p-tau217 demonstrated better performance in the identification of AD pathology and clinical phenotypes in comparison with other variants of p-tau in a memory clinic cohort. Furthermore, p-tau217 had comparable performance in plasma and CSF. Our findings suggest the potential of plasma p-tau217 in the diagnosis and screening for AD, which could allow for a decreased use of invasive biomarkers in the future.

1 March 2021 in Emotion
Verified
Journal Article
Closed access
MAMaria Amorim
Maria Amorim
AAAndrey Anikin
Andrey Anikin
AMAugusto J. Mendes
Augusto J. Mendes
CLCésar F. Lima
César F. Lima
SKSonja A. Kotz
Sonja A. Kotz
APAna P. Pinheiro
Ana P. Pinheiro
The ability to recognize emotions undergoes major developmental changes from infancy to adolescence, peaking in early adulthood, and declining with aging. A life span approach to emotion recognition is lacking in the auditory domain, and it remains unclear how the speaker's and listener's ages interact in the context of decoding vocal emotions. Here, we examined age-related differences in vocal emotion recognition from childhood until older adulthood and tested for a potential own-age bias in performance. A total of 164 participants (36 children [7-11 years], 53 adolescents [12-17 years], 48 young adults [20-30 years], 27 older adults [58-82 years]) completed a forced-choice emotion categorization task with nonverbal vocalizations expressing pleasure, relief, achievement, happiness, sadness, disgust, anger, fear, surprise, and neutrality. These vocalizations were produced by 16 speakers, 4 from each age group (children [8-11 years], adolescents [14-16 years], young adults [19-23 years], older adults [60-75 years]). Accuracy in vocal emotion recognition improved from childhood to early adulthood and declined in older adults. Moreover, patterns of improvement and decline differed by emotion category: faster development for pleasure, relief, sadness, and surprise and delayed decline for fear and surprise. Vocal emotions produced by older adults were more difficult to recognize when compared to all other age groups. No evidence for an own-age bias was found, except in children. These findings support effects of both speaker and listener ages on how vocal emotions are decoded and inform current models of vocal emotion perception. (PsycINFO Database Record (c) 2019 APA, all rights reserved).

1 January 2022 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
AMAugusto J. Mendes
Augusto J. Mendes
KPKevin Pacheco-Barrios
Kevin Pacheco-Barrios
ALAlberto Lema
Alberto Lema
ÓGÓscar F Gonçalves
Óscar F Gonçalves
FFFelipe Fregni
Felipe Fregni
Sandra CarvalhoSandra Carvalho
Sandra Carvalho

16 May 2024 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
AMAugusto J. Mendes
Augusto J. Mendes
FRFederica Ribaldi
Federica Ribaldi
ALAurélien Lathuilière
Aurélien Lathuilière
NANicholas Ashton
Nicholas Ashton
HZHenrik Zetterberg
Henrik Zetterberg
GFGiovanni B. Frisoni
Giovanni B. Frisoni
Background: Plasma biomarkers of Alzheimer’s disease (AD) pathology, neurodegeneration, and neuroinflammation are ideally suited for secondary prevention programs in self-sufficient persons at-risk of dementia. Plasma biomarkers have been shown to be highly correlated with traditional imaging biomarkers. However, their comparative predictive value versus traditional AD biomarkers is still unclear in cognitively unimpaired (CU) subjects and with mild cognitive impairment (MCI). Methods: Plasma (Aβ42/40, p-tau181, p-tau231, NfL, and GFAP) and neuroimaging (hippocampal volume, centiloid of amyloid-PET, and tau-SUVR of tau-PET) biomarkers were assessed at baseline in 218 non-demented subjects (CU = 140; MCI = 78) from the Geneva Memory Center. Global cognition (MMSE) was evaluated at baseline and at follow-ups up to 5.7 years. We used linear mixed-effects models and Cox proportional-hazards regression to assess the association between biomarkers and cognitive decline. Lastly, sample size calculations using the linear mixed-effects models were performed on subjects positive for amyloid-PET combined with tau-PET and plasma biomarker positivity. Results: Cognitive decline was significantly predicted in MCI by baseline plasma NfL (β=-0.55), GFAP (β=-0.36), hippocampal volume (β = 0.44), centiloid (β=-0.38), and tau-SUVR (β=-0.66) (all p < 0.05). Subgroup analysis with amyloid-positive MCI participants also showed that only NfL and GFAP were the only significant predictors of cognitive decline among plasma biomarkers. Overall, NfL and tau-SUVR showed the highest prognostic values (hazard ratios of 7.3 and 5.9). Lastly, we demonstrated that adding NfL to the inclusion criteria could reduce the sample sizes of future AD clinical trials by up to one-fourth in subjects with amyloid-PET positivity or by half in subjects with amyloid-PET and tau-PET positivity. Conclusions: Plasma NfL and GFAP predict cognitive decline in a similar manner to traditional imaging techniques in amyloid-positive MCI patients. Hence, even though they are non-specific biomarkers of AD, both can be implemented in memory clinic workups as important prognostic biomarkers. Likewise, future clinical trials might employ plasma biomarkers as additional inclusion criteria to stratify patients at higher risk of cognitive decline to reduce sample sizes and enhance effectiveness.

10 June 2025 in Neurology
Verified
Journal Article
Open access
AMAugusto J. Mendes
Augusto J. Mendes
FRFederica Ribaldi
Federica Ribaldi
MPMichela Pievani
Michela Pievani
CBCecilia Boccalini
Cecilia Boccalini
Valentina GaribottoValentina Garibotto
Valentina Garibotto
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
The amyloid cascade hypothesis posits that Alzheimer disease (AD) progresses from amyloid deposition to tau deposition, neurodegeneration, and eventually cognitive impairment and is the foundation of the revised criteria of Alzheimer's Association Workgroup 2024 (AA-2024). To account for copathologies and cognitive resilience that affect the penetrance of the AD cascade, AA-2024 introduced a 2-dimensional biological-clinical staging framework. We aimed to estimate the proportion of persons along the AD continuum whose biological and clinical trajectories align with the amyloid cascade. Cross-sectional data of the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort were tested in the 4 × 4 biological/clinical staging matrix adapted from the AA-2024 criteria. Biological stages were defined by amyloid and tau-PET burden: stage A (amyloid positivity, A+), stage B (medial temporal tau, A+/T2MTL+), stage C (moderate neocortical tau, A+/T2MOD+), and stage D (high neocortical tau, A+/T2HIGH+). Clinical stages were cognitively unimpaired (stage 1), subtle cognitive impairment (stage 2), mild cognitive impairment (stage 3), and dementia (stages 4-6). Tau-PET cutoffs were defined through the implementation of 5 distinct methods. Participants were categorized into (1) compliant with the amyloid cascade (matrix diagonal), (2) resilient (advanced biological stage-early clinical stage), and (3) copathologic (early biological stage-advanced clinical stage). Observed distributions were compared with hypothetical scenarios with zero and high amyloid cascade penetrance using the χ2 test, and differences among the 5 methods were tested using the Cochran Q test. Two-hundred and fifty-six amyloid-positive individuals (mean age: 72.7 years; 51% female) from the ADNI cohort were considered. The proportion of participants compliant with the amyloid cascade was between 31% (95% CI 25%-37%) and 36% (95% CI 30%-42%) depending on the tau-PET cutoff method. The observed number of individuals compliant with the amyloid cascade was higher than in the zero-penetrance scenario but lower than in the high-penetrance distribution (p < 0.01). The proportion of copathologic (17%-63%) and resilient (6%-52%) individuals varied widely by tau-PET cutoff (p < 0.001). Only approximately one-third of persons with an AA-2024 diagnosis of AD complied with the predictions of the amyloid cascade hypothesis. These results suggest the heterogeneity in how clinical symptoms and pathology are coupled along the AD continuum, which has significant implications for interpreting completed antiamyloid clinical trials and designing future studies.

24 May 2018 in Applied Psychophysiology and Biofeedback
Verified
Journal Article
Closed access
PDF file
ÓGÓscar F Gonçalves
Óscar F Gonçalves
Sandra CarvalhoSandra Carvalho
Sandra Carvalho
AMAugusto J. Mendes
Augusto J. Mendes
Jorge LeiteJorge Leite
Jorge Leite
PBPaulo S. Boggio
Paulo S. Boggio